Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer
11. Februar 2021 07:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar宣布在加拿大发布保护MNPR-101物质成分的专利
09. Februar 2021 07:00 ET
|
Monopar Therapeutics Inc.
伊利诺伊州威尔梅特, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc.（Nasdaq：MNPR）是一家临床阶段的生物制药公司，主要专注于开发旨在延长癌症患者寿命并改善其生活质量的专有疗法。该公司今天宣布在加拿大发布保护MNPR-101物质成分的专利，强化了其在包括美国、欧洲和日本在内的全球主要市场的现有保护。 ...
Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada
09. Februar 2021 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar宣布获发新型Camsirubicin类似物配方的美国专利
22. Dezember 2020 08:31 ET
|
Monopar Therapeutics Inc.
-所获专利扩大和增强了Monopar目前的camsirubicin知识产权组合-针对晚期软组织瘤的camsirubicin2期试验在2021年初启动的安排保持不变 伊利诺伊州威尔梅特, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics...
Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs
22. Dezember 2020 08:30 ET
|
Monopar Therapeutics Inc.
-Issued patent expands and strengthens Monopar’s existing camsirubicin IP portfolio-Phase 2 initiation for camsirubicin in advanced soft tissue sarcoma remains on track for early 2021 WILMETTE,...
Monopar和NorthStar宣布选定uPRIT候选药物作为重症新冠肺炎潜在治疗药物
10. Dezember 2020 08:30 ET
|
Monopar Therapeutics Inc.
伊利诺伊州威尔梅特和威斯康星州贝洛伊特, Dec. 10, 2020 (GLOBE NEWSWIRE) -- 合作开发尿激酶型纤溶酶原激活物受体放射免疫疗法（uPRIT）用于重症新冠肺炎患者潜在治疗的Monopar Therapeutics Inc.（Nasdaq: MNPR）和NorthStar Medical Radioisotopes,...
Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19
10. Dezember 2020 08:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase...
Monopar宣布启动2b/3期（VOICE）试验以评估Validive®预防化疗引起口咽癌（OPC）患者重度口腔粘膜炎（SOM）的效果。
08. Dezember 2020 08:46 ET
|
Monopar Therapeutics Inc.
伊利诺斯州威尔梅特, Dec. 08, 2020 (GLOBE NEWSWIRE) -- 主要专注于开发专有技术疗法以延长癌症患者寿命或提高其生活质量的临床分期生物制药公司Monopar Therapeutics Inc.（Nasdaq: MNPR）今天宣布，该公司运用Validive®防止口咽癌患者放化疗引发重度口腔粘膜炎的试验（以下称“VOICE”试验）2b/3期已启动并开始招募患者。 ...
Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
08. Dezember 2020 08:30 ET
|
Monopar Therapeutics Inc.
There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM WILMETTE, Ill., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a...
Monopar Therapeutics Reports Third Quarter 2020 Financial Results and Business Update
12. November 2020 09:15 ET
|
Monopar Therapeutics Inc.
Validive® Phase 2b/3 Clinical Trial on Track to Start Before Year-endIssuance of New Patents For ValidiveCamsirubicin Phase 2 Clinical Trial to Start Late 2020/Early 2021 WILMETTE, Ill., Nov. 12,...